Response to first salvage therapy in patients with relapse during/after chemotherapy
| . | Total . | B-lineage . | T-lineage . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n = 224 . | CR = 95 (42%)* . | P . | n = 159 . | CR = 73 (46%)* . | P . | n = 65 . | CR = 22 (34%)* . | P . | |
| Early relapse | 160 | 58 (36%) | > .05 | 114 | 44 (39%) | > .05 | 46 | 14 (30%) | > .05 |
| Consolidation I | 47 | 13 (28%) | 38 | 11 (29%) | 9 | 2 | |||
| FLAG-IDA | 39 | 16 (41%) | 38 | 16 (42%) | 1 | 0 | |||
| CLAEG | 16 | 3 (19%) | 0 | 0 | 16 | 3 (19%) | |||
| Standard induction | 9 | 3 | 8 | 2 | 1 | 1 | |||
| HDAC ± Mitox | 9 | 4 | 5 | 2 | 4 | 2 | |||
| HDMTX | 7 | 3 | 3 | 1 | 4 | 2 | |||
| Other chemotherapy | 15 | 6 (40%) | 8 | 4 | 7 | 2 | |||
| SCT in relapse† | 18 | 10 (56%) | 14 | 8 (57%) | 4 | 2 | |||
| Late relapse | 64 | 37 (58%) | < .0001 | 45 | 29 (64%) | .0003 | 19 | 8 (42%) | > .05 |
| CLAEG | 9 | 2 | 9 | 2 | |||||
| Standard induction | 30 | 27 (90%) | 27 | 24 (88%) | 3 | 3 | |||
| SCT in relapse† | 1 | 1 | 1 | 1 | 0 | 0 | |||
| FLAG-IDA | 15 | 4 (27%) | 14 | 4 (29%) | 1 | 0 | |||
| HDAC ± Mitox | 1 | 0 | 1 | 0 | 0 | 0 | |||
| Other | 8 | 3 | 2 | 0 | 6 | 3 | |||
| . | Total . | B-lineage . | T-lineage . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n = 224 . | CR = 95 (42%)* . | P . | n = 159 . | CR = 73 (46%)* . | P . | n = 65 . | CR = 22 (34%)* . | P . | |
| Early relapse | 160 | 58 (36%) | > .05 | 114 | 44 (39%) | > .05 | 46 | 14 (30%) | > .05 |
| Consolidation I | 47 | 13 (28%) | 38 | 11 (29%) | 9 | 2 | |||
| FLAG-IDA | 39 | 16 (41%) | 38 | 16 (42%) | 1 | 0 | |||
| CLAEG | 16 | 3 (19%) | 0 | 0 | 16 | 3 (19%) | |||
| Standard induction | 9 | 3 | 8 | 2 | 1 | 1 | |||
| HDAC ± Mitox | 9 | 4 | 5 | 2 | 4 | 2 | |||
| HDMTX | 7 | 3 | 3 | 1 | 4 | 2 | |||
| Other chemotherapy | 15 | 6 (40%) | 8 | 4 | 7 | 2 | |||
| SCT in relapse† | 18 | 10 (56%) | 14 | 8 (57%) | 4 | 2 | |||
| Late relapse | 64 | 37 (58%) | < .0001 | 45 | 29 (64%) | .0003 | 19 | 8 (42%) | > .05 |
| CLAEG | 9 | 2 | 9 | 2 | |||||
| Standard induction | 30 | 27 (90%) | 27 | 24 (88%) | 3 | 3 | |||
| SCT in relapse† | 1 | 1 | 1 | 1 | 0 | 0 | |||
| FLAG-IDA | 15 | 4 (27%) | 14 | 4 (29%) | 1 | 0 | |||
| HDAC ± Mitox | 1 | 0 | 1 | 0 | 0 | 0 | |||
| Other | 8 | 3 | 2 | 0 | 6 | 3 | |||
Responses are shown for patients with evaluable information on the type of salvage therapy without CNS involvement and with Ph/ BCR-ABL− ALL. Reproduced with permission from Gökbuget et al.16
HDAC indicates high-dose cytarabine; HDMTX, high-dose methotrexate; and Mitox, mitoxantrone.
No percentage was calculated in subgroups with total number of cases < 10.
Patients received SCT as their salvage treatment and CR rate indicates the remission rate after SCT.